S-1: Structure Therapeutics Eyes \$322 Million Boost with Public Offering

Structure Therapeutics is launching a public offering of American Depositary Shares and pre-funded warrants to fuel its clinical programs.

Summary

• Structure Therapeutics is undertaking a public offering involving 8,000,000 American Depositary Shares (ADSs), each representing three ordinary shares, and pre-funded warrants to purchase ordinary shares represented by ADSs.
• The company aims to raise approximately \$322 million through this offering.
• The offering includes an option for underwriters to purchase an additional 1,200,000 ADSs.
• The funds are intended to advance the development of oral small molecule therapeutics, particularly GSBR-1290 for obesity and T2DM, and to support other research and development activities.
• The company plans to use the proceeds to fund Phase 2b and Phase 3 studies for GSBR-1290, as well as preclinical and Phase 1 studies for other programs like ANPA-0073 and LTSE-2578.
• The offering also aims to advance next-generation GLP-1R candidates and combination therapies.
• Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, and Leerink Partners are acting as representatives for the underwriters.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the company's clinical progress and future plans. However, it also acknowledges the risks and challenges inherent in drug development and the company's financial situation.

Positives

• The offering will provide substantial capital to advance Structure Therapeutics' key clinical programs, particularly GSBR-1290.
• The company has multiple ongoing clinical programs with topline data expected in the near future.
• The company has a strong intellectual property portfolio with patents expiring between 2039 and 2045.
• GSBR-1290 has demonstrated significant weight loss and HbA1c reduction in clinical trials.
• The company has a diversified pipeline targeting metabolic, cardiovascular, and pulmonary diseases.

Negatives

• The company has a limited operating history and has incurred significant operating losses since its inception.
• The company will require substantial additional capital to finance its operations.
• The company's approach to drug discovery is unproven, and it may not be able to develop commercially valuable products.
• The company is early in its development efforts, with only two product candidates in early clinical development.
• Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes.
• The company relies on third parties for the manufacture of its product candidates.
• The company conducts certain research and development operations through its Australian wholly-owned subsidiaries, and any loss of ability to operate in Australia could affect the business.

Risks

• The company may use the proceeds of the offering ineffectively.
• Investors will experience immediate dilution of their investment.
• Future equity offerings may result in further dilution.
• There is no public market for the pre-funded warrants being issued.
• Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes.
• The company relies on third parties for the manufacture of its product candidates.
• Changes in the political and economic policies or in relations between China and the United States may affect the business.
• The company may be required to obtain approval or prior permission of this offering from the CSRC or any other Chinese regulatory authority under the Chinese laws and regulations currently in effect.

Future Outlook

The company anticipates submitting an IND to the FDA in the third quarter of 2024 to support initiation of a trial in chronic weight management and expects to initiate a global Phase 2b study for obesity in the fourth quarter of 2024. Details of the Phase 2 development plan in T2DM are expected to be determined in the second half of 2024. Based on the current business plan, the company estimates that its existing cash, cash equivalents and short-term investments as of the date of this prospectus, together with the estimated net proceeds from this offering, will be sufficient to fund its projected operations through at least 2027.

Industry Context

Structure Therapeutics is operating in the competitive biopharmaceutical industry, specifically targeting chronic diseases with unmet medical needs. The company's focus on oral small molecule therapeutics for GPCRs positions it against companies developing biologics and peptide therapies. The GLP-1R programs target the large and growing markets of obesity and T2DM, competing with established injectable GLP-1R agonists and other emerging oral therapies.

Comparison to Industry Standards

• Structure Therapeutics' GSBR-1290 is an oral small molecule GLP-1R agonist, differentiating it from injectable peptide GLP-1R agonists like Ozempic (Novo Nordisk) and Trulicity (Eli Lilly).
• The company's approach leverages structure-based drug discovery, aiming to overcome limitations of biologics and peptide therapies.
• The company's LPA1R program, LTSE-2578, targets idiopathic pulmonary fibrosis (IPF), a market with existing treatments like Ofev (Boehringer Ingelheim) and Esbriet (Roche), but with room for improved oral therapies.
• The company's APJR agonist, ANPA-0073, is being evaluated for selective or muscle-sparing weight loss, potentially offering a unique benefit compared to other weight loss drugs.

Stakeholder Impact

• Shareholders: Potential dilution from the offering, but also potential for increased value if clinical programs are successful.
• Employees: Continued employment and potential for new hires to support research and development activities.
• Customers: Potential for new and improved oral therapeutics for chronic diseases.
• Suppliers: Continued business relationships and potential for increased demand for manufacturing and research services.
• Creditors: No immediate impact expected.

Next Steps

• Submit an IND to the FDA in the third quarter of 2024 to support initiation of a trial in chronic weight management.
• Initiate a global Phase 2b study for obesity in the fourth quarter of 2024.
• Determine details of the Phase 2 development plan in T2DM in the second half of 2024.

Key Dates

Keywords

Structure Therapeutics, public offering, ADS, pre-funded warrants, GSBR-1290, GLP-1R, obesity, T2DM, clinical trials, biopharmaceutical, ANPA-0073, LTSE-2578, FDA, GPCR, small molecule therapeutics